If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-12. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Serotonylation has been reported in various cell types and tissues, including both serotonergic and dopaminergic neurons, enterochromaffin cells, cancer-associated fibroblasts, pancreatic 𝛽-cells, CD8+ T cells, pulmonary endothelial cells, platelets, neutrophils, mammary epithelial cells, vascular smooth muscle, and cells of the intestines. Serotonylation is known to influence both tumorigenesis and cancer metastasis, and has been implicated in several types of cancer, including colorectal cancer, neuroendocrine prostate cancer, pancreatic cancer, hepatocellular carcinoma, and ependymomas (brain cancer).
Paleofeces, also known as coprolites (though that name is more commonly used in reference to animal feces), are ancient human feces, often found as part of archaeological excavations or surveys. Intact feces of ancient people may be found in caves in arid climates and in other locations with suitable preservation conditions. These are studied to determine the diet and health of the people who produced them through the analysis of seeds, small bones, and parasite eggs found inside. They also may be analyzed chemically for more in-depth information on the individual who excreted them, using lipid analysis and DNA analysis. The success rate of usable DNA extraction is relatively high in paleofeces, making it more reliable than skeletal DNA retrieval.
=== Amplifying fluorescent polymer === Amplifying fluorescent polymer (AFP) is a promising new technology and is based on synthesized polymers which bind to explosive molecules and give an amplified signal upon detection. When compounds that are not polymers are utilized for such purpose, the quenching of the fluorescence by the traces of explosives is not detectable. When amplifying fluorescent polymer in thin films absorbs a photon of light, excited state polymers (excitons) are able to migrate along the polymer backbone and between the adjacent polymer films. These sensors were originally made in order to detect trinitrotoluene. In AFP, binding of one TNT molecule results in quenching of fluorescence significantly due to the conjugated structure of the polymers. It has been reported that in practice the polymers result in 100-1000 fold increase of amplification of the quenching response. "During its excited state lifetime, the exciton propagates by a random walk through a finite volume of the polymer film." Once TNT, or any other electron-deficient (i.e., electron accepting) molecule comes in contact with the polymer, a so-called low-energy ‘trap’ forms. "If the exciton migrates to the site of the bound electron-deficient molecule before transitioning back to the ground state, the exciton will be trapped (a non-radioactive process), and no fluorescence will be observed from the excitation event.
=== Analogues and derivatives === Analogues and derivatives of 2,5-DMA include the DOx series like DOM, DOB, and DOI, FLY compounds like DOB-FLY, Bromo-DragonFLY (DOB-DFLY), DOH-5-hemiFLY, 25-NB compounds like DOM-NBOMe, DOB-NBOMe, and DOI-NBOMe, and other compounds like trimethoxyamphetamines (TMAs) and pentamethoxyamphetamine (PeMA). Methoxamine (β-hydroxy-2,5-DMA) is another derivative of 2,5-DMA.
Halim, Adilla Nur; Abdul Rani, Aidatul Azura; et al. (Kadri, Rozeeda; Abdul Aziz, Farhana; Ridzuan, Mohd Naufal; Hassan, Ali Noor; Wazir, Maznah; Arzeni, Lydiawati) (2017). Amalan Perubatan Tradisional Melayu bagi Penjagaan Ibu-Ibu Selepas Bersalin di Negeri Kelantan [Traditional Malay Medical Practices for Postpartum Maternal Care in Kelantan] (PDF) (in Malay). Traditional and Complementary Medicine Practice Branch, Traditional and Complementary Medicine Division, Ministry of Health of Malaysia. pp. 1–90. ISBN 978-983-44782-9-2. Archived (PDF) from the original on 2 June 2025. Mazliadiyana, M; Nazrun, AS; Isa, NM (2017). "Optimum Dose of Sea Cucumber (Stichopus Chloronotus) Extract for Wound Healing" (PDF). Med & Health. 12 (1): 83–89. doi:10.17576/MH.2017.1201.09. Devi Oktaviani, Paramita; Wahjuningsih, Endah; Andriani, Dwi (2018). "Efektivitas Suplementasi Teripang Emas (Stichopus Hermanii) Dalam Mencegah Terjadinya Oral Candidiasis Pada Tikus Wistar" [Effectivity of Stichopus hermanii Supplementation to Prevent Oral Candidiasis on Rats]. Denta (Jurnal Kedokteran Gigi) (in Indonesian). 12 (1): 9–15. doi:10.30649/denta.v12i1.155. ISSN 1907-5987. Archived from the original on 1 June 2025. Text is licensed by DENTA (Journal Kedokteran Gigi) under CC BY-NC-SA 4.0 Hafiz Leong, Muhamad Nur; Mohd Fauzi, Noor Akhmazillah; Rahim Kamarudin, Kamarul; Mohamed Rehan, Aisyah (2021). "Investigation of Bioactive Compounds from Sea Cucumber Extract and Stingless Bee Honey Using Critical Literature Review and Bioinformatics Approach for Potential Synergy Combination".
Sources: en.wikipedia.org
Scott Boatwright, Chief Executive Officer and Board member Adam Rymer, Chief Financial Officer Curt Garner, President, Chief Strategy and Technology Officer Ilene Eskenazi, Chief Legal and Human Resources Officer Jason Kidd, Chief Operating Officer Laurie Schalow, Chief Corporate Affairs Officer Kerry Bridges, Chief Food Safety Officer
=== Off-label drugs === α2-Adrenergic receptor agonists (e.g., clonidine, guanfacine) Anticonvulsants/mood stabilizers (e.g., valproic acid, lamotrigine) Antipsychotics (non-licensed) (e.g., haloperidol, olanzapine) Cannabinoids (e.g., cannabis, dronabinol, nabilone) Dietary supplements (e.g., N-acetylcysteine, omega-3 fatty acids, sulforaphane) Entactogens (serotonin releasing agents) (e.g., MDMA) Melatonin receptor agonists (e.g., melatonin) NMDA receptor antagonists (e.g., memantine, amantadine) Norepinephrine reuptake inhibitors (NRIs) (e.g., atomoxetine) Opioid receptor antagonists (e.g., naltrexone) Other antidepressants (e.g., mirtazapine) Oxytocin receptor agonists (e.g., oxytocin) Probiotics and prebiotics Psychostimulants (norepinephrine–dopamine releasing agents and/or reuptake inhibitors) (e.g., amphetamine, methylphenidate) Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, sertraline, citalopram) Serotonergic psychedelics (e.g., psilocybin, lysergic acid diethylamide (LSD)) Serotonin–norepinephrine reuptake inhibitors (SNRIs) (e.g., milnacipran) Serotonin releasing agents (e.g., fenfluramine—withdrawn and no longer recommended) Serotonin 5-HT1A receptor agonists (e.g., buspirone) Tricyclic antidepressants (TCAs) (e.g., clomipramine)
Arenobufagin is believed to play a role in the regulation of the transport of water and electrolytes across cell membranes under physiological conditions. Experimental results show that Arenobufagin inhibits the sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) . It is one of the most potent blockers that are known to science, along with ouabain. It has been suggested that uncharged and non-polar amino acids may participate in the binding of arenobufagin to the extracellular surface of the ATPase. If this is the case, the steroid nucleus of arenobufagin probably also contributes to the binding. Furthermore, the presence of a sugar group in ouabain and the absence of one in arenobufagin suggests that it may me more lipophilic that ouabain and as such form a more stable complex with the Na+-K+ pump. Besides its effects on the Na+-K+ pump, arenobufagin also has some other effects on cells, which were discovered in experiment with cancer cell lines. It causes apoptosis by tempering with mitochondria. In cells treated with it, a decreasing mitochondrial potential was detected (in a dose-dependent manner), as well as a high Bax/Bcl-2 ratio, which is associated with apoptosis, or programmed cell death. Bax translocation from cytosol to mitochondria was also found to be increased. In addition to these effects, arenobufagin also induces morphological changes in organelles, blebbing of plasma membrane, shrinkage of nuclear membrane and chromatin condensation. These observation also indicate the occurrence of apoptosis.
Fermentation is a type of anaerobic metabolism that harnesses the redox potential of the reactants to make adenosine triphosphate (ATP) and organic end products. Organic molecules, such as glucose or other sugars, are catabolized and their electrons are transferred to other organic molecules (cofactors, coenzymes, etc.). Anaerobic glycolysis is a related term used to describe the occurrence of fermentation in organisms (usually multicellular organisms such as animals) when aerobic respiration cannot keep up with the ATP demand, due to insufficient oxygen supply or anaerobic conditions. Fermentation is important in several areas of human society. Humans have used fermentation in the production and preservation of food for 13,000 years. It has been associated with health benefits, unique flavor profiles, and making products have better texture. Humans and their livestock also benefit from fermentation from the microbes in the gut that release end products that are subsequently used by the host for energy. Perhaps the most commonly known use for fermentation is at an industrial level to produce commodity chemicals, such as ethanol and lactate. Ethanol is used in a variety of alcoholic beverages (beers, wine, and spirits) while lactate can be neutralized to lactic acid and be used for food preservation, as a curing agent, or as a flavoring agent. This complex metabolism utilizes a wide variety of substrates and can form nearly 300 different combinations of end products. Fermentation occurs in both prokaryotes and eukaryotes.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.